FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320729669> ?p ?o ?g. }

• W4320729669 endingPage "435" @default.
• W4320729669 startingPage "435" @default.
• W4320729669 abstract "It is widely accepted that SARS-CoV-2 causes a dysregulation of immune and coagulation processes. In severely affected patients, viral sepsis may result in life endangering multiple organ dysfunction. Furthermore, most therapies for COVID-19 patients target either the immune system or coagulation processes. As the exact mechanism causing SARS-CoV-2-induced morbidity and mortality was unknown, we started an in-depth analysis of immunologic and coagulation processes.127 COVID-19 patients were treated at the University Hospital Essen, Germany, between May 2020 and February 2022. Patients were divided according to their maximum COVID-19 WHO ordinal severity score (WHO 0-10) into hospitalized patients with a non-severe course of disease (WHO 4-5, n = 52) and those with a severe course of disease (WHO 6-10, n = 75). Non-infected individuals served as healthy controls (WHO 0, n = 42). Blood was analyzed with respect to cell numbers, clotting factors, as well as pro- and anti-inflammatory mediators in plasma. As functional parameters, phagocytosis and inflammatory responses to LPS and antigen-specific stimulation were determined in monocytes, granulocytes, and T cells using flow cytometry.In the present study, immune and coagulation systems were analyzed simultaneously. Interestingly, many severe COVID-19 patients showed an upregulation of pro-inflammatory mediators and at the same time clear signs of immunosuppression. Furthermore, severe COVID-19 patients not only exhibited a disturbed immune system, but in addition showed a pronounced pro-coagulation phenotype with impaired fibrinolysis. Therefore, our study adds another puzzle piece to the already complex picture of COVID-19 pathology implying that therapies in COVID-19 must be individualized.Despite years of research, COVID-19 has not been understood completely and still no therapies exist, fitting all requirements and phases of COVID-19 disease. This observation is highly reminiscent to sepsis. Research in sepsis has been going on for decades, while the disease is still not completely understood and therapies fitting all patients are lacking as well. In both septic and COVID-19 patients, immune activation can be accompanied by immune paralysis, complicating therapeutic intervention. Accordingly, therapies that lower immune activation may cause detrimental effects in patients, who are immune paralyzed by viral infections or sepsis. We therefore suggest individualizing therapies and to broaden the spectrum of immunological parameters analyzed before therapy. Only if the immune status of a patient is understood, can a therapeutic intervention be successful." @default.
• W4320729669 created "2023-02-15" @default.
• W4320729669 creator A5000630452 @default.
• W4320729669 creator A5001746120 @default.
• W4320729669 creator A5016243200 @default.
• W4320729669 creator A5016532166 @default.
• W4320729669 creator A5020685597 @default.
• W4320729669 creator A5022853632 @default.
• W4320729669 creator A5033237508 @default.
• W4320729669 creator A5038167432 @default.
• W4320729669 creator A5040483582 @default.
• W4320729669 creator A5048243572 @default.
• W4320729669 creator A5054183679 @default.
• W4320729669 creator A5063516762 @default.
• W4320729669 creator A5065192051 @default.
• W4320729669 creator A5087456839 @default.
• W4320729669 creator A5090117715 @default.
• W4320729669 date "2023-02-13" @default.
• W4320729669 modified "2023-10-15" @default.
• W4320729669 title "Patients with SARS-CoV-2-Induced Viral Sepsis Simultaneously Show Immune Activation, Impaired Immune Function and a Procoagulatory Disease State" @default.
• W4320729669 cites W1229030346 @default.
• W4320729669 cites W1758328146 @default.
• W4320729669 cites W1975466068 @default.
• W4320729669 cites W2051083932 @default.
• W4320729669 cites W2076961991 @default.
• W4320729669 cites W2097599737 @default.
• W4320729669 cites W2137274600 @default.
• W4320729669 cites W2280404143 @default.
• W4320729669 cites W2291784480 @default.
• W4320729669 cites W2917920609 @default.
• W4320729669 cites W2943888800 @default.
• W4320729669 cites W2944331050 @default.
• W4320729669 cites W3001118548 @default.
• W4320729669 cites W3002108456 @default.
• W4320729669 cites W3010604545 @default.
• W4320729669 cites W3013240402 @default.
• W4320729669 cites W3014003872 @default.
• W4320729669 cites W3018517500 @default.
• W4320729669 cites W3018529391 @default.
• W4320729669 cites W3019247800 @default.
• W4320729669 cites W3020168167 @default.
• W4320729669 cites W3039983944 @default.
• W4320729669 cites W3042989521 @default.
• W4320729669 cites W3047168254 @default.
• W4320729669 cites W3047402958 @default.
• W4320729669 cites W3048320561 @default.
• W4320729669 cites W3049583880 @default.
• W4320729669 cites W3082201689 @default.
• W4320729669 cites W3091085673 @default.
• W4320729669 cites W3093261446 @default.
• W4320729669 cites W3099192040 @default.
• W4320729669 cites W3105146261 @default.
• W4320729669 cites W3112902030 @default.
• W4320729669 cites W3126898707 @default.
• W4320729669 cites W3140915421 @default.
• W4320729669 cites W3142457473 @default.
• W4320729669 cites W3160282671 @default.
• W4320729669 cites W3161021894 @default.
• W4320729669 cites W3161705187 @default.
• W4320729669 cites W3167521026 @default.
• W4320729669 cites W3171559423 @default.
• W4320729669 cites W3182386410 @default.
• W4320729669 cites W3205584395 @default.
• W4320729669 cites W3208342532 @default.
• W4320729669 cites W3209588830 @default.
• W4320729669 cites W3210386674 @default.
• W4320729669 cites W4200140746 @default.
• W4320729669 cites W4206989777 @default.
• W4320729669 cites W4221026046 @default.
• W4320729669 cites W4224947610 @default.
• W4320729669 cites W4225370592 @default.
• W4320729669 cites W4226184226 @default.
• W4320729669 cites W4281562250 @default.
• W4320729669 cites W4284969624 @default.
• W4320729669 doi "https://doi.org/10.3390/vaccines11020435" @default.
• W4320729669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36851312" @default.
• W4320729669 hasPublicationYear "2023" @default.
• W4320729669 type Work @default.
• W4320729669 citedByCount "1" @default.
• W4320729669 countsByYear W43207296692023 @default.
• W4320729669 crossrefType "journal-article" @default.
• W4320729669 hasAuthorship W4320729669A5000630452 @default.
• W4320729669 hasAuthorship W4320729669A5001746120 @default.
• W4320729669 hasAuthorship W4320729669A5016243200 @default.
• W4320729669 hasAuthorship W4320729669A5016532166 @default.
• W4320729669 hasAuthorship W4320729669A5020685597 @default.
• W4320729669 hasAuthorship W4320729669A5022853632 @default.
• W4320729669 hasAuthorship W4320729669A5033237508 @default.
• W4320729669 hasAuthorship W4320729669A5038167432 @default.
• W4320729669 hasAuthorship W4320729669A5040483582 @default.
• W4320729669 hasAuthorship W4320729669A5048243572 @default.
• W4320729669 hasAuthorship W4320729669A5054183679 @default.
• W4320729669 hasAuthorship W4320729669A5063516762 @default.
• W4320729669 hasAuthorship W4320729669A5065192051 @default.
• W4320729669 hasAuthorship W4320729669A5087456839 @default.
• W4320729669 hasAuthorship W4320729669A5090117715 @default.
• W4320729669 hasBestOaLocation W43207296691 @default.
• W4320729669 hasConcept C126322002 @default.

• next